South America and the World Health Organization’s goals for the elimination of cervical cancer
DOI:
https://doi.org/10.21527/2176-7114.2025.50.14919Keywords:
HPV vaccine, Cervical cancer, Screening programs, Public healthAbstract
The World Health Organization (WHO) has established strategic targets to eliminate cervical cancer by 2030. This study evaluates the progress of South American countries toward meeting these targets. Population estimates for South American countries were obtained from the WHO website, the HPV and Cancer Information Center of the Catalan Institute of Oncology (ICO), and the International Agency for Research on Cancer (IARC). In terms of vaccination coverage, Guyana, Colombia, and Suriname reported the lowest first-dose coverage rates, while Guyana, Colombia, Paraguay, and Suriname had the lowest second-dose coverage. Screening coverage exceeded 70% in Argentina, Uruguay, Paraguay, Colombia, Chile, and Peru over the past 5 yr. In terms of treatment, the highest incidence-to-mortality ratios were observed in Suriname (0.62), Uruguay (0.58), Venezuela (0.57), and Argentina (0.56). The findings highlight significant challenges, particularly in Suriname and Venezuela, emphasizing the urgent need for effective public policies and international support to help these countries meet the 2030 targets through strategic and financial interventions.
References
1. Gattegno MV, Vertamatti MAF, Bednarczyk RA, Evans DP. A cross-sectional survey of parental attitudes towards Human papillomavirus vaccination exclusion categories in Brazil. BMC Int Health Hum Rights. 2019 Feb 28;19(1):6.
2. Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021 May 12;21(1):894.
3. Buitrago Reyes LA, Gamboa Garay OA, Hernández JA. Age, period and cohort effects on mortality from cervical cancer in Colombia between 1985 and 2014. Colomb Med. 2022 Mar 30;53(1):e2074873.
4. Scott-Wittenborn N, Fakhry C. Epidemiology of HPV Related Malignancies. Semin Radiat Oncol. 2021 Oct;31(4):286–96.
5. Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021 Mar;144:106399.
6. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023 Feb;11(2):e197–206.
7. Shadab R, Lavery JV, McFadden SM, Elharake JA, Malik F, Omer SB. Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule. Hum Vaccin Immunother. 2022 Dec 31;18(1):1917231.
8. Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2023 Jan 4;41(1):236–45.
9. World Health Organization. Cervical Cancer Country Profiles [Internet]. Geneva: WHO; 2021 [consulted on 2 February 2023]. Available from: https://www.who.int/teams/noncommunicable-diseases/surveillance/data/cervicalcancer-profiles
10. Grunberg MG, Chan M, Adhin MR. Distinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination. Epidemiol Infect. 2017 Jan;145(2):245–53.
11. Website [Internet]. Available from: https://www.state.gov/reports/2022-investment-climate-statements/guyana/
12. Cerqueira RS, Dos Santos HLPC, Prado NM de BL, Bittencourt RG, Biscarde DGDS, Dos Santos AM. [Control of cervical cancer in the primary care setting in South American countries: systematic reviewControl del cáncer cervicouterino en los servicios de atención primaria de salud en los países de América del Sur: revisión sistemática]. Rev Panam Salud Publica. 2022 Aug 18;46:e107.
13. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Aug 21;320(7):674–86.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Context and Health Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
